Ameet Nathwani, Dewpoint Therapeutics CEO (L.Chamussy/Viva Tech/Sipa via AP Images)

Dew­point Ther­a­peu­tics re­struc­tures to ‘make room’ for en­try in­to the clin­ic next year in on­col­o­gy, ALS

Con­den­sate mod­u­la­tor start­up Dew­point Ther­a­peu­tics is go­ing through a re­struc­tur­ing as it gears up for its first clin­i­cal tri­als next year in col­orec­tal can­cer and amy­otroph­ic lat­er­al scle­ro­sis, CEO Ameet Nath­wani told End­points News.

The biotech will let go 18 po­si­tions, about 15% of its staff, as it tran­si­tions from a dis­cov­ery-stage start­up to a drug de­vel­op­ment com­pa­ny, Nath­wani said in an in­ter­view on Wednes­day morn­ing. STAT News first re­port­ed the moves Tues­day af­ter­noon.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA